Literature DB >> 23504512

A PCA approach to population analysis: with application to a Phase II depression trial.

Eleonora Marostica1, Alberto Russu, Roberto Gomeni, Stefano Zamuner, Giuseppe De Nicolao.   

Abstract

For psychiatric diseases, established mechanistic models are lacking and alternative empirical mathematical structures are usually explored by a trial-and-error procedure. To address this problem, one of the most promising approaches is an automated model-free technique that extracts the model structure directly from the statistical properties of the data. In this paper, a linear-in-parameter modelling approach is developed based on principal component analysis (PCA). The model complexity, i.e. the number of components entering the PCA-based model, is selected by either cross-validation or Mallows' Cp criterion. This new approach has been validated on both simulated and clinical data taken from a Phase II depression trial. Simulated datasets are generated through three parametric models: Weibull, Inverse Bateman and Weibull-and-Linear. In particular, concerning simulated datasets, it is found that the PCA approach compares very favourably with some of the popular parametric models used for analyzing data collected during psychiatric trials. Furthermore, the proposed method performs well on the experimental data. This approach can be useful whenever a mechanistic modelling procedure cannot be pursued. Moreover, it could support subsequent semi-mechanistic model building.

Entities:  

Mesh:

Year:  2013        PMID: 23504512     DOI: 10.1007/s10928-013-9304-6

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  17 in total

1.  Analyzing incomplete longitudinal clinical trial data.

Authors:  Geert Molenberghs; Herbert Thijs; Ivy Jansen; Caroline Beunckens; Michael G Kenward; Craig Mallinckrodt; Raymond J Carroll
Journal:  Biostatistics       Date:  2004-07       Impact factor: 5.899

2.  The Scree Test For The Number Of Factors.

Authors:  R B Cattell
Journal:  Multivariate Behav Res       Date:  1966-04-01       Impact factor: 5.923

3.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

4.  Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.

Authors:  Gijs Santen; Meindert Danhof; Oscar Della Pasqua
Journal:  J Psychiatr Res       Date:  2008-03-18       Impact factor: 4.791

5.  Using disease progression models as a tool to detect drug effect.

Authors:  D R Mould; N G Denman; S Duffull
Journal:  Clin Pharmacol Ther       Date:  2007-05-16       Impact factor: 6.875

6.  Bayesian population modeling of phase I dose escalation studies: Gaussian process versus parametric approaches.

Authors:  Alberto Russu; Italo Poggesi; Roberto Gomeni; Giuseppe De Nicolao
Journal:  IEEE Trans Biomed Eng       Date:  2011-08-15       Impact factor: 4.538

7.  Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.

Authors:  Gianluca Nucci; Roberto Gomeni; Italo Poggesi
Journal:  Expert Opin Drug Discov       Date:  2009-06-24       Impact factor: 6.098

Review 8.  Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Authors:  Roberto Gomeni; Agnes Lavergne; Emilio Merlo-Pich
Journal:  Eur J Pharm Sci       Date:  2008-11-08       Impact factor: 4.384

9.  Validity of the depressive dimension extracted from principal component analysis of the PANSS in drug-free patients with schizophrenia.

Authors:  Meriem El Yazaji; Omar Battas; Mohamed Agoub; Driss Moussaoui; Christel Gutknecht; Jean Dalery; Thierry d'Amato; Mohamed Saoud
Journal:  Schizophr Res       Date:  2002-07-01       Impact factor: 4.939

10.  Principal components analysis to summarize microarray experiments: application to sporulation time series.

Authors:  S Raychaudhuri; J M Stuart; R B Altman
Journal:  Pac Symp Biocomput       Date:  2000
View more
  2 in total

1.  Continuous-time Markov modelling of flexible-dose depression trials.

Authors:  Eleonora Marostica; Alberto Russu; Roberto Gomeni; Stefano Zamuner; Giuseppe De Nicolao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-04       Impact factor: 2.745

2.  Exploring population pharmacokinetic modeling with resampling visualization.

Authors:  Fenghua Zuo; Jun Li; Xiaoyong Sun
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.